We’ve refreshed our website! Take a look around, tell us what you think, or revisit the archived site.
Join us at the 2026 MDF regional conference - Happening in a city near you!
Join the monthly newsletter called MyDispatch - Keeping you up to date in research advances

MDF UK - formerly the Wyck Foundation

Originally established in 2015 as the Wyck Foundation, was founded in London by a dedicated group of individuals committed to supporting global efforts to improve the quality of life for those living with myotonic dystrophy (DM). MDF UK's sister organisation, the Myotonic Dystrophy Foundation (MDF) in the United States, remains steadfast in carrying forward the mission that MDF UK so passionately championed.

Community, Care, and a Cure.

In December 2024, after nine impactful years, the Trustees of Myotonic Dystrophy Foundation UK (MDF UK) made the difficult decision to cease operations, believing it was in the best interests of the charity and its mission.

Thank you to all the donors who supported MDF UK over the years. Their generosity and commitment made it possible to fund groundbreaking research and support critical advancements. Special recognition goes to those who donated in memory or honor of loved ones—these contributions have left a lasting legacy, propelling the field closer to better treatments and a cure for myotonic dystrophy.

As MDF UK concludes its journey, the community is encouraged to continue supporting MDF’s global efforts to improve care and find a cure. 

MDF UK grants & funding

For nearly a decade, MDF UK contributed significantly to the progress in the field of DM. The organisation funded 16 research grants and 22 fellowships, each playing a critical role in advancing understanding of this complex disease and bringing researchers closer to a cure.

In partnership with the Myotonic Dystrophy Foundation in the United States, MDF UK funded a range of important research projects, including the successful Research Fellowship Programme, which provides two-year pre- and postdoctoral fellowships. Many fellows have continued their work in the field, contributing meaningful progress in understanding DM and developing future treatments.

  • “Mechanisms of DM1 Cardiac Pathogenesis and Potential Therapeutics
    Rong-Chi Hu, Baylor College of Medicine, Houston, Texas, US
  • “Brain Choroid Plexus Dysregulation and Cerebral Atrophy in DM1”
    Benjamin M. Kidd, University of Florida, Gainesville, Florida, US
  • “Discovery of Dietary Natural Compounds as Potential Therapeutics for Myotonic Dystrophy (DM)”
    Subodh Kumar Mishra, PhD, The RNA Institute, University of Albany, New York, US
  • “Reach DM- Study to Promote Trial Readiness by Genetic Analysis and Telemedicine Assessments”
    PI: Johanna Hamel, MD, University of Rochester, New York, US
  • “Targeting the RNA that Causes DM2 for Degradation with Small Molecules”
    Raphael Benhamou, PhD, Scripps Research Institute, Florida, US
  • “Novel Strategy Targeting Muscle Stem Cells as a Therapeutic Approach for Myotonic Dystrophy Type 1”
    Talita Conte, PhD, University of Montreal, Canada
  • “Improving the Activity of Diamidines for Potential Therapeutic Use for Patients with Myotonic Dystrophy Types 1 and 2”
    Jana Jenquin, PhD, University of Florida, Gainesville, Florida, US
  • “Restoration of MBNL Proteins Through miRNA Blocking as DM1 Therapy”
    Sarah Overby, Incliva, University of Valencia, Spain
  • “Selective and Non-toxic Small Molecules that Cleave r(CUG) Repeats in DM1—Optimization and Evaluation as a Therapeutic Approach”
    Shruti Choudhary, PhD, Scripps Research Institute Florida, US
  • “Engineering Synthetic RNA Binding Proteins to Probe the Mechanisms of Myotonic Dystrophy and Development of Potential New Therapeutics”
    Carl Shotwell, University of Florida, Gainesville, Florida, US
  • “Request for Support for Publication and Open Access Fee for a Peer-Reviewed Myotonic Dystrophy Therapy Review Paper”
    PI: Ruben Aretero, PhD, University of Valencia, Spain
  • “Myotonic Dystrophy Clinical Research Network (DMCRN) Site Grants: Multicentre Study of Natural History and Genetic Modifiers in Myotonic Dystrophy Type 1”
    PI: Nicholas Johnson, MD, Virginia Commonwealth University, Virginia, US
  • “CRISPRI-induced Transcriptional Silencing of DMPK as a Therapeutic Strategy Against Myotonic Dystrophy Type 1”
    Florent Porquet, University of Liege, Belgium
  • “Congenital Myotonic Dystrophy: Pathomechanism and Therapeutic Development”
    Curtis Nutter, PhD, University of Florida, Gainesville, Florida, US
  • “Tissue Specific Expression of Expanded CUG Repeat RNA to Investigate the Cardiac Pathogenesis of Myotonic Dystrophy Type 1”
    Ashish Rao, Baylor College of Medicine, Houston, Texas, US
  • “Molecular Characterization of RNA and RAN Protein Effects in DM2”
    Kiruphagaran Thangaraju, PhD, University of Florida, Gainesville, Florida, US
  • “Biomarker Qualification Project”
    Jane Larkindale, DPhil, Critical Path Institute, US
  • “Mechanism of CNS-associated Behavioral Dysfunction in Novel Mouse Model of Myotonic Dystrophy Type 1”
    Anwesha Banerjee, PhD, Emory University, Atlanta, Georgia, US
  • “Pre-clinical Investigations of Small Molecule-mediated Targeting of Toxic RNA Production in DM2”
    Kaalak Reddy, PhD, University of Florida, Gainesville, Florida, US
  • “Workshop Support – Myotonic Dystrophy: Developing a European Consortium for Care and Therapy”
    PI: Alexandra Breukel, PhD, European Neuromuscular Centre, Netherlands
  • “Prevalence of Myotonic Dystrophy”
    PI: Nicholas E. Johnson, MD, University of Utah, US
  • “PHENO-DM1- Myotonic Dystrophy type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials”
    PI: Hanns Lochmüller, MD, Newcastle University, UK
  • “Development of Magnetic Resonance Imaging as an Endpoint in Myotonic Dystrophy Type 1”
    PI: Donovan Lott, PhD, University of Florida, US
  • “Building a Better Mouse”
    PI: Cathleen Lutz, PhD, The Jackson Laboratory, US
  • “DM Cell Line Library”
    PI: Michael Sheldon, PhD, RUCDR Infinite Biologics, Rutgers University, US
  • “Extracellular RNA as Biomarkers of Myotonic Dystrophy”
    PI: Thurman Wheeler, MD, Massachusetts General Hospital, US
  • “Inhibiting Transcription of CUG/CCUG Expanded Repeats with Small Molecules”
    PI: Andy Berglund, PhD (University of Florida), PI: Paul August, PhD (Sanofi)
  • “Studying Genome-Wide MBNL-RNA Structure Interactions in Neuronal Development and DM”
    Ranjan Batra, PhD, University of California, San Diego, California, US
  • “Precise Lead Therapeutics for Myotonic Dystrophy via in cellulo Synthesis”
    Viachaslau Bernat, PhD, Scripps Research Institute Florida, US
  • “An Investigation of the Cellular and Microbial Etiologies of Gastrointestinal Pathologies in Myotonic Dystrophy Zebrafish”
    Melissa Hinman, PhD, University of Oregon, Eugene, Oregon, US